Enigma Biomedical selects two 4R Tau PET biomarkers

Enigma Biomedical USA, Inc. has announced two promising biomarker candidates to begin Phase 1 studies. These candidates are focused on imaging the four-repeat tau (4R Tau) protein, which is linked to neurodegenerative diseases such as Progressive Supranuclear Palsy and Corticobasal Degeneration. Earlier, Enigma Biomedical signed a licensing agreement with AbbVie to develop advanced PET imaging biomarkers that can detect 4R Tau in patients suspected of having neurodegenerative conditions. The goal is to enhance understanding and treatment of these diseases. The Phase 1 studies will evaluate safety and effectiveness, including how the biomarkers are taken up and cleared from the body. These studies are expected to start in the third quarter of 2025. Rick Hiatt, the President and CEO of Enigma Biomedical, expressed enthusiasm about moving into clinical stages. He emphasized the company's commitment to accelerating new technologies in the fight against neurodegenerative diseases. Hartmuth Kolb, the Chief Science Officer, shared that the studies will analyze various characteristics of the biomarkers to identify the best candidates for further development. The hope is that these new imaging tools will help improve treatments for patients with neurodegenerative diseases.